Analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to report ($0.97) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Wave Life Sciences’ earnings. The highest EPS estimate is ($0.60) and the lowest is ($1.45). Wave Life Sciences posted earnings per share of ($1.23) during the same quarter last year, which indicates a positive year-over-year growth rate of 21.1%. The firm is expected to announce its next quarterly earnings results on Thursday, August 8th.

On average, analysts expect that Wave Life Sciences will report full year earnings of ($3.90) per share for the current financial year, with EPS estimates ranging from ($5.82) to ($1.69). For the next financial year, analysts expect that the business will post earnings of ($4.91) per share, with EPS estimates ranging from ($5.83) to ($3.58). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that follow Wave Life Sciences.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Friday, May 10th. The company reported ($1.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by ($0.17). The firm had revenue of $3.03 million during the quarter, compared to the consensus estimate of $9.66 million. Wave Life Sciences had a negative return on equity of 146.23% and a negative net margin of 971.48%.

A number of brokerages have recently commented on WVE. BidaskClub lowered shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Zacks Investment Research lowered shares of Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 9th. HC Wainwright reaffirmed a “buy” rating and set a $33.00 target price on shares of Wave Life Sciences in a research report on Monday. Finally, ValuEngine lowered shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 25th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $53.75.

In related news, insider Michael A. Panzara sold 7,000 shares of Wave Life Sciences stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $48.00, for a total transaction of $336,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Paul Bolno sold 50,000 shares of Wave Life Sciences stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $45.48, for a total transaction of $2,274,000.00. The disclosure for this sale can be found here. Company insiders own 44.20% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. Quantamental Technologies LLC purchased a new position in Wave Life Sciences in the fourth quarter worth $29,000. Citigroup Inc. lifted its stake in shares of Wave Life Sciences by 189.4% during the fourth quarter. Citigroup Inc. now owns 2,807 shares of the company’s stock worth $118,000 after buying an additional 1,837 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in shares of Wave Life Sciences by 17.9% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,045 shares of the company’s stock worth $118,000 after buying an additional 462 shares during the period. Amundi Pioneer Asset Management Inc. lifted its stake in shares of Wave Life Sciences by 45.0% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 2,900 shares of the company’s stock worth $122,000 after buying an additional 900 shares during the period. Finally, Legal & General Group Plc lifted its stake in shares of Wave Life Sciences by 17.9% during the fourth quarter. Legal & General Group Plc now owns 3,094 shares of the company’s stock worth $130,000 after buying an additional 469 shares during the period. 75.37% of the stock is currently owned by institutional investors.

NASDAQ WVE traded down $0.67 during trading on Wednesday, hitting $27.05. The stock had a trading volume of 328,687 shares, compared to its average volume of 463,354. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.56 and a quick ratio of 1.56. The company has a market cap of $927.77 million, a P/E ratio of -5.33 and a beta of 0.56. Wave Life Sciences has a one year low of $22.90 and a one year high of $56.00.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Featured Article: Closed-End Mutual Funds

Get a free copy of the Zacks research report on Wave Life Sciences (WVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.